• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
【24h】

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

机译：黑色素瘤脑转移瘤患者应考虑大剂量白介素2（HD IL-2）治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University. There were 5 men and 3 women; median age was 52.2 years (26.8–61.1 years). One patient started treatment with lung lesions only (after resection of melanoma brain disease) and experienced partial response. Seven patients had brain metastases at treatment initiation. Median overall survival (mOS) for entire cohort (n=8) was 8.7 months (2.1 to 19.0 months). All patients with brain metastases at first dose (n=7) showed progressive disease; mOS was 6.7 months (range 2.1–18.2 months) for this group. Patients received radiosurgery and whole brain radiation before and after HD IL-2 therapy. One patient had symptoms suggestive of neurotoxicity. A history of alcohol abuse was revealed during admission. The patient's symptoms improved with initiation of an alcohol withdrawal protocol. In this analysis, patients with melanoma brain metastases received HD IL-2 without treatment-related mortality. We think that HD IL-2 should be considered as a treatment option in patients with melanoma brain metastases who are otherwise eligible for therapy.
机译：从1999年1月至2011年6月在圣路易斯大学对接受HD IL-2治疗的稳定黑色素瘤脑转移患者（静脉注射720,000 IU / kg; 14剂，每疗程2个周期，最多2个疗程）进行了回顾性研究。 。男5例，女3例。中位年龄为52.2岁（26.8–61.1岁）。一名患者仅在切除黑色素瘤脑病后才开始治疗肺部病变，并出现部分反应。七名患者在治疗开始时发生脑转移。整个队列（n = 8）的中位总体生存期（mOS）为8.7个月（2.1至19.0个月）。所有在第一剂量（n = 7）有脑转移的患者均显示进行性疾病。该组的mOS为6.7个月（范围2.1-18.2个月）。在HD IL-2治疗前后，患者接受了放射外科手术和全脑放射。一名患者的症状表明存在神经毒性。入院期间发现有酗酒史。开始戒酒方案可以改善患者的症状。在该分析中，患有黑色素瘤脑转移的患者接受了HD IL-2，而没有与治疗相关的死亡率。我们认为，HD IL-2应该被视为在其他情况下有资格接受治疗的黑色素瘤脑转移患者的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号